Answers are grounded in this paper and cite their sources.
Clinical trials for cognitively unimpaired β-amyloid-positive individuals will include a large number of individuals where mechanisms downstream from β-amyloid pathology are already activated. These findings have implications for primary and secondary prevention of Alzheimer's disease.
No takes yet. Share an insight, caveat, or question.
Insel et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: